Vincerx Pharma Stock Today
| VINC Stock | USD 0.72 0.11 13.25% |
PerformanceVery Weak
| Odds Of DistressVery High
|
Vincerx Pharma is trading at 0.72 as of the 19th of March 2025, a 13.25 percent decrease since the beginning of the trading day. The stock's open price was 0.83. Vincerx Pharma has a very high chance of experiencing financial distress in the next few years of operation. It has also generated negative returns for investors over the last 90 days. The performance scores are derived for the period starting the 19th of December 2024 and ending today, the 19th of March 2025. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 27th of May 2020 | Category Healthcare | Classification Health Care |
Vincerx Pharma, Inc., a clinical-stage biopharmaceutical company, researches and develops therapies to address unmet medical needs for the treatment of cancer in the United States. Vincerx Pharma, Inc. was founded in 2019 is headquartered in Palo Alto, California. The company has 30.88 M outstanding shares of which 108.52 K shares are at this time shorted by private and institutional investors with about 0.8 trading days to cover. More on Vincerx Pharma
Moving together with Vincerx Stock
Moving against Vincerx Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
Vincerx Stock Highlights
| Chairman CoFounder | Ahmed MD | |||||||||||||||||||||||||||||||||||
| Thematic Idea | Pharmaceutical Products (View all Themes) | |||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Health Care, Pharmaceutical Products, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||
Debt LevelsVincerx Pharma can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Vincerx Pharma's financial leverage. It provides some insight into what part of Vincerx Pharma's total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||
Vincerx Pharma (VINC) is traded on NASDAQ Exchange in USA. It is located in 260 Sheridan Avenue, Palo Alto, CA, United States, 94306 and employs 42 people. Vincerx Pharma is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Micro-Cap' category with a current market capitalization of 10.48 M. Vincerx Pharma conducts business under Biotechnology sector and is part of Health Care industry. The entity has 30.88 M outstanding shares of which 108.52 K shares are at this time shorted by private and institutional investors with about 0.8 trading days to cover.
Vincerx Pharma currently holds about 80.86 M in cash with (40.45 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.82, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check Vincerx Pharma Probability Of Bankruptcy
Ownership AllocationVincerx Pharma shows a total of 30.88 Million outstanding shares. 30% of Vincerx Pharma outstanding shares are owned by institutional holders. Institutional investors are typically referred to investors that purchase positions in a given stock to benefit from reduced commissions. Consequently, institutional investors are subject to different rules and regulations than regular investors. Please look out for any change in current institutional holding as this could mean something significant has changed at the company or is about to change. Please note that no matter how many assets the company owns, if the real value of the company is less than the current market value, you may not be able to make money on it.
Check Vincerx Ownership Details
Vincerx Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Susquehanna International Group, Llp | 2024-12-31 | 21.4 K | |
| Jane Street Group Llc | 2024-12-31 | 11.2 K | |
| The Colony Group Llc | 2024-12-31 | 10.9 K | |
| Morgan Stanley - Brokerage Accounts | 2024-12-31 | 2.1 K | |
| Bank & Trust Co | 2024-12-31 | 1000 | |
| Sbi Securities Co Ltd | 2024-12-31 | 1000 | |
| Bank Of America Corp | 2024-12-31 | 237 | |
| Jpmorgan Chase & Co | 2024-12-31 | 23.0 | |
| Goldman Sachs Group Inc | 2024-12-31 | 0.0 | |
| Sage Rhino Capital Llc | 2024-12-31 | 1.7 M | |
| Rock Springs Capital Management Lp | 2024-12-31 | 891.7 K |
Vincerx Pharma Historical Income Statement
Vincerx Stock Against Markets
Vincerx Pharma Corporate Management
| Raj MBA | VP Manufacturing | Profile | |
| Melissa SPHR | Director Culture | Profile | |
| Karen Quarford | Vice Compliance | Profile | |
| Karen MBA | Vice Compliance | Profile |
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Vincerx Pharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. For information on how to trade Vincerx Stock refer to our How to Trade Vincerx Stock guide.You can also try the Analyst Advice module to analyst recommendations and target price estimates broken down by several categories.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Vincerx Pharma. If investors know Vincerx will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Vincerx Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Vincerx Pharma is measured differently than its book value, which is the value of Vincerx that is recorded on the company's balance sheet. Investors also form their own opinion of Vincerx Pharma's value that differs from its market value or its book value, called intrinsic value, which is Vincerx Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Vincerx Pharma's market value can be influenced by many factors that don't directly affect Vincerx Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Vincerx Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Vincerx Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Vincerx Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.